The rapid evolution of medical technology has profoundly transformed the diagnosis, treatment, and management of chronic and life threatening diseases. Among the most complex and impactful innovations are cardiac implantable electronic devices such as pacemakers and defibrillators, advanced therapy medicinal products, and novel regulatory pathways that seek to balance patient access with safety and effectiveness. Traditional randomized controlled trials have long been considered the gold standard for evidence generation in medicine. However, these trials are limited in duration, population diversity, and the capacity to capture rare or long term outcomes. As a result, real world evidence has emerged as a critical complement to conventional clinical trials, offering insights derived from routine clinical practice, registries, electronic health records, and post approval surveillance systems.

This article presents an in depth, theoretically grounded, and empirically informed exploration of how real world evidence, regulatory science, and patient centered pharmacovigilance can be integrated to improve the safety and effectiveness assessment of complex medical technologies. Drawing strictly on the provided references, the analysis focuses particularly on cardiac implantable devices such as pacemakers and defibrillators, including leadless pacing systems, and their interactions with diagnostic modalities such as magnetic resonance imaging. The risks associated with MRI in patients with implanted cardiac devices represent a paradigmatic example of how premarket testing alone is insufficient to capture the full spectrum of real world safety issues. The seminal work by Russo and colleagues demonstrated how large scale, carefully designed clinical investigations can challenge longstanding assumptions about device related risks, thereby reshaping clinical guidelines and regulatory frameworks (Russo et al., 2017).

At the same time, the development of regulatory concepts such as real world evidence has been formally articulated by regulatory authorities and academic leaders, who have emphasized its potential to support regulatory decision making, label expansions, and postmarket surveillance (Sherman et al., 2016). The growing reliance on real world data is also reflected in large observational studies, such as the nationwide cohort analysis of antipsychotic treatments in schizophrenia, which illustrates how treatment effectiveness and safety can be evaluated at a scale and in populations that randomized trials rarely reach (Tiihonen et al., 2017).